18 results
Thumbnail

D2.165 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Pediatric Asthma: A Cross-Sectional Study from Mexico City

Thumbnail

D2.167 - Impact of body mass index on oscillometry parameters in children with respiratory symptoms

Thumbnail

D2.168 - Impact of type two inflammation inflamation suppression on polyp burden in patients with nasal polyposis and concomitant asthma a comparative evaluation of biologic therapies

Thumbnail

D2.171 - Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study

Thumbnail

D2.172 - Effectiveness of Mepolizumab in patients with severe asthma and allergic rhinitis: Real-World Evidence from the TYREX Study

Thumbnail

D2.173 - Real-World Evidence From the TYREX Study on the effectiveness of Mepolizumab in patients with severe asthma and clinically relevant aeroallergen sensitization

Thumbnail

D2.174 - Association Between Environmental Conditions and Mold Sensitization in Children with Allergic Rhinitis and Asthma

Thumbnail

D2.175 - Five-Year Real-World Outcomes of Mepolizumab Treatment in Severe Eosinophilic Asthma

Thumbnail

D2.176 - Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma

Thumbnail

D2.179 - Chronic cough triggered by industrialised milk and wheat products

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study